The susceptibility to teicoplanin, vancomycin and linezolid of 30 clinical isolates of Enterococcus faecium was tested by Vitek 2, Phoenix, Etest, broth microdilution and disc diffusion tests. The vanA and vanB resistance genes and the 23S rRNA gene G2576T mutation were detected by PCR and PCR-RFLP, respectively. Resistance rates to teicoplanin ranged from 3 % for Vitek 2 to 57.6 % for the Phoenix test, and those to vancomycin ranged from 56.7 % for Vitek 2 to 86.7 % for the Phoenix test. Only two out of 25 strains carrying the vanA gene were univocally recognized as the VanA phenotype. The only strain with the G2576T mutation did not carry the vanA gene and showed resistance to linezolid by the disc diffusion, Vitek 2 and broth dilution methods (MIC >8 μg ml−1), but was susceptible when tested with the Phoenix test and Etest (MIC ≤4 μg ml−1). Therefore, the resistance to glycopeptides and linezolid was not univocally detected by the susceptibility testing methods used in this study.
Abele-HornM.,
HommersL.,
TraboldR.,
FroschM.2006; Validation of VITEK 2 version 4.01 software for detection, identification, and classification of glycopeptides-resistant enterococci. J Clin Microbiol 44:71–76[CrossRef]
DeshpandeL. M.,
FritscheT. R.,
MoetG. J.,
BiedenbachD. J.,
JonesR. N.2007; Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 58:163–170[CrossRef]
Garcia-GarroteF.,
CercenadoE.,
BouzaE.2000; Evaluation of a new system, VITEK 2, for identification and antimicrobial susceptibility testing of enterococci. J Clin Microbiol 38:2108–2111
JonesR. N.,
FritscheT. R.,
SaderH. S.,
RossJ. E.2007; LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centres). Diagn Microbiol Infect Dis 59:309–317[CrossRef]
KobayashiI.,
MuraokaH.,
IyodaT.,
NishidaM.,
HasegawaM.,
YamaguchiK.2004; Antimicrobial susceptibility testing of vancomycin-resistant Enterococcus by the Vitek system, and comparison with two NCCLS reference methods. J Med Microbiol 53:1229–1232[CrossRef]
LeeW. G.,
HuhJ. Y.,
ChoS. R.,
LimY. A.2004; Reduction in glycopeptide resistance in vancomycin-resistant enterococci as a result of vanA cluster rearrangements. Antimicrob Agents Chemother 48:1379–1381[CrossRef]
NNIS2001; National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992–June 2001, issued August 2001. Am J Infect Control 29:404–421[CrossRef]
PendleS.,
JeftsP.,
OlmaT.,
SuY.,
GilroyN.,
GilbertG. L.2008; Difficulties in detection and identification of Enterococcus faecium with low-level inducible resistance to vancomycin, during a hospital outbreak. Clin Microbiol Infect 14:853–857[CrossRef]
RuggeroK. A.,
SchroederL. K.,
SchreckenbergerP. C.,
MankinA. S.,
QiunnJ. P.2003; Nosocomial superinfections due to linezolid-resistant Enterococcus faecalis : evidence for a gene dosage effect on linezolid MICs. Diagn Microbiol Infect Dis 47:511–513[CrossRef]
ScheetzM. H.,
QiC.,
NoskinG. A.,
WarrenJ. R.,
PostelnickM. J.,
MalczynskiM.,
HuangJ.,
ZembowerT. R.2006; The clinical impact of linezolid susceptibility reporting in patients with vancomycin-resistant enterococci. Diagn Microbiol Infect Dis 56:407–413[CrossRef]
TenoverF. C.,
WilliamsP. P.,
StockerS.,
ThompsonA.,
ClarkL. A.,
LimbagoB.,
CareyR. B.,
PoppeS. M.,
ShinabargerD.,
McGowanJ. E.Jr2007; Accuracy of six antimicrobial susceptibility methods for testing linezolid against staphylococci and enterococci. J Clin Microbiol 45:2917–2922[CrossRef]
van den BraakN.,
GoessensW.,
van BelkumA.,
VerbrughH. A.,
EndtzH. P.2001; Accuracy of the VITEK 2 system to detect glycopeptides resistance in enterococci. J Clin Microbiol 39:351–353[CrossRef]